A team of German scientists and biotech company Dynamic42 have jointly developed a ‘tumour-on-chip’ model of pancreatic ...

Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...

The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer ...

Through this study, we aim to offer a new, innovative treatment to patients,” medical oncologist Dr. John Lenehan said.

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...

Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP ...

The statement unites the cancer community in opposing recent executive actions and calling on both the administration and ...

Dr. Makary argues for more humility from the medical establishment and common sense when reviewing experimental drugs for ...

REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

Me, once valued at $6 billion, is now a penny stock. Layoffs, data breaches, and resignations led to its downfall. How did it ...